GSK to buy US cancer biotech IDRx for up to US$1.15 billion
GSK agreed to buy US biotech IDRx for as much as US$1.15 billion to gain new cancer medicines. The UK drugmaker ...
GSK agreed to buy US biotech IDRx for as much as US$1.15 billion to gain new cancer medicines. The UK drugmaker ...
Forbes 40under40 stands as a distinguished platform revered for its commitment to honoring and applauding the remarkable achievements of exceptional individuals who have yet to reach the age of 40. This esteemed initiative serves as a beacon of inspiration, spotlighting trailblazers across various industries and domains, showcasing their innovation, leadership, and impact on a global scale.
© 2025 Forbes 40under40. All Rights Reserved.